Chih-Chiang Chen

Chih-Chiang Chen

Auto-generated profile, based on publicly available information

Chih-Chiang Chen

Department of Dermatology, Taipei Veterans General Hospital , Taipei

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2022 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
YWY.‐C. Wang
Y.‐C. Wang
YLY.‐H. Lin
Y.‐H. Lin
SMS.‐H. Ma
S.‐H. Ma
YCY.‐T. Chang
Y.‐T. Chang
CCC.‐C. Chen
C.‐C. Chen

25 January 2024 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
CCChing-Li Chen
Ching-Li Chen
CWChun-Ying Wu
Chun-Ying Wu
YCYen-Ling Chen
Yen-Ling Chen
CCChih-Chiang Chen
Chih-Chiang Chen
YCYun-Ting Chang
Yun-Ting Chang
CWChen-Yi Wu
Chen-Yi Wu
Background: Vitiligo is reportedly associated with several ocular abnormalities. However, the relationship between vitiligo and retinal detachment (RD) remains unclear. Objectives: To examine the risk of RD in patients with vitiligo. Methods: A nationwide population-based cohort study was conducted using data from the Taiwan National Health Insurance Database from 2007 to 2018. A total of 21 132 patients with vitiligo were matched in a 1 : 4 ratio with people without vitiligo by age, sex and comorbidity propensity score. Cumulative incidence and Cox proportional hazard models were used to investigate the risk of RD in patients with vitiligo. Subgroup analysis was performed. Results: The cohort with vitiligo had a significantly higher rate of RD than the cohort without vitiligo [adjusted hazard ratio (aHR) 1.44, 95% confidence interval (CI) 1.20–1.72; P < 0.001]. Patients with vitiligo who required treatments such as phototherapy, systemic corticosteroids or immunosuppressants exhibited an even greater risk of RD (aHR 1.57, 95% CI 1.16–2.14; P = 0.004). Conclusions: Our study revealed a 1.44-fold increased risk of RD in patients with vitiligo, with an even higher risk in patients receiving phototherapy, systemic corticosteroids or immunosuppressants. The risk remained consistently higher over a 10-year follow-up period.

16 April 2025 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
SMSheng-Hsiang Ma
Sheng-Hsiang Ma
CYCian-Hao Yeh
Cian-Hao Yeh
TCTai-Li Chen
Tai-Li Chen
CWChen-Yi Wu
Chen-Yi Wu
CCChih-Chiang Chen
Chih-Chiang Chen
Background: The long-term sequelae of Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are increasingly being recognized. However, few studies have evaluated the long-term risk of cardiovascular diseases in these patients. Objectives: This study aimed to investigate the long-term cardiovascular outcomes in survivors of SJS/TEN. Methods: In total, 2738 SJS/TEN survivors and 2738 propensity-score-matched controls were enrolled from the US Collaborative Network in the TriNetX database. The primary outcome of this study was the development of a major cardiovascular event (MACE). Patients were followed up from 3 months after the index date until the first diagnosis of an outcome event, withdrawal from the database, or 5 January 2025. Results: We found that SJS/TEN survivors had a significantly elevated risk of MACE [hazard ratio (HR) 2.13], ischaemic heart disease (HR 1.57), cerebrovascular disease (HR 2.13) and mortality (HR 1.94) compared with the matched healthy controls. Additionally, the association remained significant in most stratifications, including female, different age groups, disease severity (SJS, SJS/TEN overlap syndrome and TEN) and initial hospitalization status. Conclusions: Some potential confounders may not be acquired in the database. In addition, detection bias is another potential source of bias in this study. This study revealed that SJS/TEN survivors have a significantly higher long-term risk of developing MACE. Understanding these sequelae may provide insights for the holistic care of SJS/TEN survivors.

12 December 2025 in The Journal of Dermatology
Verified
Journal Article
Closed access
YLYu‐Hsiang Lin
Yu‐Hsiang Lin
YWYu‐Ching Wang
Yu‐Ching Wang
TCTai-Li Chen
Tai-Li Chen
LJLing‐Chuan Jaun
Ling‐Chuan Jaun
CTCheng‐Jui Tsai
Cheng‐Jui Tsai
SMSheng‐Hsiang Ma
Sheng‐Hsiang Ma

1 January 2025 in Dermatologic Therapy
Verified
Journal Article
Open access
YLYu-Hsiang Lin
Yu-Hsiang Lin
YWYu-Ching Wang
Yu-Ching Wang
CWChen-Yi Wu
Chen-Yi Wu
YCYun-Ting Chang
Yun-Ting Chang
CCChih-Chiang Chen
Chih-Chiang Chen
Background: Janus kinase inhibitors (JAKis) have revolutionised the management of immune‐mediated inflammatory diseases (IMIDs); however, their potential to increase the risk of herpes zoster (HZ) remains a major concern. Methods: A literature search was performed through February 2024. Phase II, III and IV randomised controlled trials (RCTs) and long‐term extension (LTE) studies comparing JAKis with placebo, methotrexate or tumour necrosis factor inhibitors (TNFis) in IMIDs were included. The primary outcome was the risk ratio (RR) for HZ with JAKis compared to placebo/methotrexate or TNFis. Secondary outcomes included incidence rate ratios (IRRs) for HZ comparing JAKis with active treatments during long‐term follow‐up. Results: A total of 94 RCTs and 30 LTE studies, representing 120,698.3 patient‐years, were included. Pairwise meta‐analysis demonstrated a significantly increased HZ risk with JAKis compared with placebo/methotrexate (RR 1.98, 95% CI 1.56–2.50) and TNFis (RR 2.31, 95% CI 1.73–3.07). Network meta‐analysis identified that in rheumatoid arthritis and psoriatic arthritis, upadacitinib 30 mg significantly increased HZ risk compared with placebo (IRR 2.76, 95% CI 1.58–4.85; IRR 3.54, 95% CI 1.48–8.50) and TNFis (IRR 5.30, 95% CI 3.19–8.81; IRR 10.76, 95% CI 4.78–24.22). In atopic dermatitis, abrocitinib 200 mg was associated with a higher HZ risk compared to placebo (IRR 4.97, 95% CI 1.58–15.60) and dupilumab (IRR 4.85, 95% CI 1.55–15.22). Tofacitinib 10 mg exhibited a higher HZ risk in inflammatory bowel disease compared to placebo (IRR 8.93, 95% CI 1.16–68.53). Patients with atopic dermatitis demonstrated the highest incidence of HZ in both short‐ and long‐term analyses. The risk of HZ was dose‐dependent across all conditions. Conclusions: JAKi use was significantly associated with an elevated HZ risk in IMIDs, demonstrating a consistent dose–response relationship. These findings emphasise the importance of HZ vaccination before initiating JAKi therapy, particularly for patients on higher doses or long‐term treatment.